• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David E. Avigan, MD

Publications

  • Ballen K, Mendizabal AM, Cutler C, Politikos I, Jamieson K, Shpall EJ, Dey BR, Attar E, McAfee S, Delaney C, McCarthy P, Ball ED, Kamble R, Avigan D, Maziarz RT, Ho VT, Koreth J, Alyea E, Soiffer R, Wingard JR, Boussiotis V, Spitzer TR, Antin JH.Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation.Biol Blood Marrow Transplant. 2012 Dec;18(12):1851-8.
    22766223
  • Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee CH, Pandolfi PP.A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance.Nat Med. 2012 Sep;18(9):1350-8.
    22902876
  • Vasir B, Zarwan C, Ahmad R, Crawford KD, Rajabi H, Matsuoka K, Rosenblatt J, Wu Z, Mills H, Kufe D, Avigan D.Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC).J Immunother. 2012 Sep;35(7):555-69.
    22892452
  • Tan CS, Bord E, Broge TA, Glotzbecker B, Mills H, Gheuens S, Rosenblatt J, Avigan D, Koralnik IJ.Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy.J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):244-8.
    22549384
  • Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D.Lenalidomide enhances anti-myeloma cellular immunity.Cancer Immunol Immunother. 2012 Jun 24.
    22733396
  • Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D.Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.Blood. 2011 Jan 13;117(2):393-402.
    21030562
  • Rosenblatt J, Bissonnette A, Ahmad R, Wu Z, Vasir B, Stevenson K, Zarwan C, Keefe W, Glotzbecker B, Mills H, Joyce R, Levine JD, Tzachanis D, Boussiotis V, Kufe D, Avigan D.Immunomodulatory effects of vitamin D: implications for GVHD.Bone Marrow Transplant. 2010 Sep;45(9):1463-8.
    20081878
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
    20385792
  • Richardson PG, Soiffer RJ, Antin JH, Uno H, Jin Z, Kurtzberg J, Martin PL, Steinbach G, Murray KF, Vogelsang GB, Chen AR, Krishnan A, Kernan NA, Avigan DE, Spitzer TR, Shulman HM, Di Salvo DN, Revta C, Warren D, Momtaz P, Bradwin G, Wei LJ, Iacobelli M, McDonald GB, Guinan EC.Defibrotide for the treatment of severe hepatic veno-occlusive disease and multi-organ failure post stem cell transplantation: a multi-center, randomized, dose-finding trial.Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17.
    20167278
  • Yin L, Ahmad R, Kosugi M, Kufe T, Vasir B, Avigan D, Kharbanda S, Kufe D.Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function.Mol Pharmacol. 2010 Aug;78(2):166-74.
    20444960
  • Avigan D, Tzachanis D.Cancer vaccines in hematologic malignancies: advances, challenges and therapeutic potential.Expert Review Of Vaccines. 2010 May;9(5):451-4.
    20450317
  • Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D.Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.J Immunother.;33(2):155-66.
    20145548
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
    20118399
  • Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC.Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.J Clin Oncol. 2009 Dec 1;27(34):5713-9.
    19786667
  • Stroopinsky D, Avivi I, Rowe JM, Avigan D, Katz T.Allogeneic induced human FOXP3(+)IFN-gamma(+) T cells exhibit selective suppressive capacity.Eur J Immunol. 2009 Oct;39(10):2703-15.
    19634189
  • Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA.Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.J Clin Oncol. 2009 Jul 20;27(21):3518-25.
    19528374
  • Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D.Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells.Cancer Res. 2009 Jun 15;69(12):5133-41.
    19491255
  • Rosenblatt J, Avigan D.Cellular immunotherapy for multiple myeloma.Best Pract Res Clin Haematol. 2008 Sep;21(3):559-77. Review.
    18790455
  • Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP.PML targeting eradicates quiescent leukaemia-initiating cells.Nature. 2008 Jun 19;453(7198):1072-8.
    18469801
  • Kawano T, Ito M, Raina D, Wu Z, Rosenblatt J, Avigan D, Stone R, Kufe D.MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.Cancer Res. 2007 Dec 15;67(24):11576-84.
    18089786
  • Maithel SK, Pratt W, Kelleher T, Avigan D, Goldman H, Pfeifer W, Pihan GA, Vollmer CM.Autoimmune pancreatitis in the setting of Castleman disease.Pancreas. 2007 Nov;35(4):384-7.
    18090252
  • Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma.J Immunother. 2007 Oct;30(7):749-61.
    17893567
  • Avigan DE, Vasir B, George DJ, Atkins MB, McDermott DM, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM.Phase I/II Study of Vaccination with Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients with Stage IV Renal Cell Carcinoma.J Immunol. 2007;In Press.
  • Ballen KK, Shpall EJ, Avigan D, Yeap BY, Fisher DC, McDermott K, Dey BR, Attar E, McAfee S, Konopleva M, Antin JH, Spitzer TR.Phase I trial of parathyroid hormone to facilitate stem cell mobilization.Biol Blood Marrow Transplant. 2007 Jul;13(7):838-43.
    17580262
  • Kawano T, Agata N, Kharbanda S, Avigan D, Kufe D.A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells.Cancer Chemother Pharmacol. 2007 Feb;59(3):329-35.
    16830153
  • Borges VF, Kufe D, Avigan DE.Update on cancer vaccines.Curr Opin Gastroenterol. 2002 Nov;18(6):723-31.
    17033355
  • Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ,.Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study.Biol Blood Marrow Transplant. 2006 Jul;12(7):778-85.
    16785067
  • Lenahan C, Avigan D.Dendritic cell defects in patients with cancer: mechanisms and significance.Breast Cancer Res. 2006;8(1):101.
    16469120
  • Avigan D.Advances in the development of a therapeutic cancer vaccine.J Natl Compr Canc Netw. 2005 Nov;3 Suppl 1:S2-6.
    16280106
  • Avigan D.Advances in the Development of a Therapeutic Cancer Vaccine.Journal of National Comprehensive Cancer Network. 2005 Nov 03;S2-S6((Suppl1)).
  • Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D.Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.Br J Haematol. 2005 Jun;129(5):687-700.
    15916692
  • Rosenblatt J, Kufe D, Avigan D.Dendritic cell fusion vaccines for cancer immunotherapy.Expert Opin Biol Ther. 2005 May 05;5:703-15.
  • Antin JH, Guinan EC, Avigan D, Soiffer RJ, Joyce RM, Martin VJ, Molrine DC.Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2005 Mar;11(3):213-22.
    15744240
  • Vasir B, Avigan D, Wu Z, Crawford K, Turnquist S, Ren J, Kufe D.Dendritic cells induce MUC1 expression and polarization on human T cells by an IL-7-dependent mechanism.J Immunol. 2005 Feb 15;174(4):2376-86.
    15699174
  • Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L.Innovations and challenges in renal cancer: consensus statement from the first international conference.Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6277S-81S.
    15448017
  • Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, Atkins M, Mier J, McDermott D, Smith T, Giallambardo N, Stone C, Schadt K, Dolgoff J, Tetreault JC, Villarroel M, Kufe D.Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses.Clin Cancer Res. 2004 Jul 15;10(14):4699-708.
    15269142
  • Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol. 2004 May;125(3):343-52.
    15086415
  • Joyce RM, Regan M, Ottaway J, Umiel T, Tetreault JC, Levine J, McDermott D, Hurley D, Giallombardo N, Smith T, Lamontagne D, Uhl L, Avigan D.A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT).Ann Oncol. 2003;14 Suppl 1:i21-7.
    12736227
  • Schwaber MJ, Krasner CN, Gold HS, Venkataraman L, Avigan DE, Karchmer AW, Uhl L.Detection of Staphylococcus aureus in peripheral blood stem cell cultures after sterilization of standard blood cultures.J Clin Apheresis. 2003;18(1):37-9.
    12717792
  • Avigan D.Fusions of breast cancer and dendritic cells as a novel cancer vaccine.Clin Breast Cancer. 2003 Feb;3 Suppl 4:S158-63.
    12620154
  • Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.Blood. 2002 Dec 15;100(13):4337-43.
    12393437
  • Elias AD, Ibrahim J, Richardson P, Avigan D, Joyce R, Reich E, McCauley M, Wheeler C, Frei E.The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe.Biol Blood Marrow Transplant. 2002;8(4):198-205.
    12017145
  • Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D.Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.Blood. 2002 Apr 1;99(7):2512-7.
    11895787
  • Exley MA, Tahir SM, Cheng O, Shaulov A, Joyce R, Avigan D, Sackstein R, Balk SP.A major fraction of human bone marrow lymphocytes are Th2-like CD1d-reactive T cells that can suppress mixed lymphocyte responses.J Immunol. 2001 Nov 15;167(10):5531-4.
    11698421
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, McDermott D, Levine J, Warren D, McCauley M, Wheeler C, Frei E.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies.Bone Marrow Transplant. 2001 Sep;28(5):447-54.
    11593317
  • Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D.Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.Eur J Haematol Suppl. 2001 Jul(64):56-62.
    11486404
  • Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L.A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.Bone Marrow Transplant. 2001 Feb;27(3):269-78.
    11277174
  • Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, Levine J, Kennedy L, Giallombardo N, Hurley D, Gong J, Kufe D.Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer.Bone Marrow Transplant. 2000 Jul;26(2):169-76.
    10918427
  • Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, Cannistra S, Avigan D, Kufe D.Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity.J Immunol. 2000 Aug 1;165(3):1705-11.
    10903782
  • Gong J, Avigan D, Chen D, Wu Z, Koido S, Kashiwaba M, Kufe D.Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2715-8.
    10688917
  • Frei E, Richardson P, Avigan D, Bunnell C, Wheeler C, Elias A.The interval between courses of high-dose chemotherapy with stem cell rescue: therapeutic hypotheses.Bone Marrow Transplant. 1999 Nov;24(9):939-45.
    10556951
  • Avigan D, Wu Z, Gong J, Joyce R, Levine J, Elias A, Richardson P, Milano J, Kennedy L, Anderson K, Kufe D.Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoin.Clin Cancer Res. 1999 Oct;5(10):2735-41.
    10537336
  • Avigan D.Dendritic cells: development, function and potential use for cancer immunotherapy.Blood Rev. 1999 Mar;13(1):51-64.
    10225609